{
    "ok": true,
    "doi": "10.46243/jst.2020.v5.i04.pp223-229",
    "references_in_record": 10,
    "not_read": [],
    "own_doi": [],
    "total": 10,
    "page": 1,
    "pages": 1,
    "per_page": 20,
    "items": [
        {
            "position": 1,
            "key": "ref1",
            "doi": "10.1016/j.ejpb.2015.10.001",
            "doi_url": "https://doi.org/10.1016/j.ejpb.2015.10.001",
            "unstructured": "Du Plessis LH, Govender K, Denti P, Wiesner L. In vivo efficacy and bioavailability of lumefantrine : Evaluating the application of Pheroid technology. Eur J Pharm Biopharm. 2015; 97:68-77",
            "held": false
        },
        {
            "position": 2,
            "key": "ref2",
            "doi": "10.1186/2008-2231-21-27",
            "doi_url": "https://doi.org/10.1186/2008-2231-21-27",
            "unstructured": "Patel K, Sarma V, Vavia P. Design and evaluation of lumefantrine–oleic acid self-nanoemulsifying ionic complex for enhanced dissolution. DARU J Pharm Sci. 2013; 21(1):1-11",
            "held": false
        },
        {
            "position": 3,
            "key": "ref3",
            "doi": "10.2165/00003088-199937020-00002",
            "doi_url": "https://doi.org/10.2165/00003088-199937020-00002",
            "unstructured": "White NJ, vanVugt M, Ezzet FD. Clinical pharmacokinetics and pharmacody namics of ar temether-lumefant rine. Clin Pharmacokinet. 1999; 37(2):105-125",
            "held": false
        },
        {
            "position": 4,
            "key": "ref4",
            "doi": "10.1128/aac.01382-13",
            "doi_url": "https://doi.org/10.1128/aac.01382-13",
            "unstructured": "Wahajuddin M, Raju KS, Singh SP, Taneja I. Investigation of the functional role of P-glycoprotein in limiting the oral bioavailability of lumefantrine. Antimicrob Agents Chemother. 2014; 58(1):489- 494",
            "held": false
        },
        {
            "position": 5,
            "key": "ref5",
            "doi": "10.1016/j.colsurfb.2012.01.047",
            "doi_url": "https://doi.org/10.1016/j.colsurfb.2012.01.047",
            "unstructured": "Gahoi S, Jain GK, Tripathi R, Pandey SK, Anwar M, Warsi MH, Singhal M, Khar RK, Ahmad, FJ. Enhanced antimalarial activity of lumefantrine nanopowder prepared by wet-milling DYNO MILL technique. Colloids Surf B Biointerfaces. 2012; 95:16-22. 228 | P ag e",
            "held": false
        },
        {
            "position": 6,
            "key": "ref6",
            "doi": "10.1016/j.ijpharm.2016.10.064",
            "doi_url": "https://doi.org/10.1016/j.ijpharm.2016.10.064",
            "unstructured": "Garg A, B halala K, T omar D S. I n-situ s ingle p ass i ntestinal permeability and pharmacokinetic study of developed lumefantrine loaded solid lipid nanoparticles. Int J Pharm. 2017; 516(1-2):120-130",
            "held": false
        },
        {
            "position": 7,
            "key": "ref7",
            "doi": "10.2174/15672018113109990044",
            "doi_url": "https://doi.org/10.2174/15672018113109990044",
            "unstructured": "Bhatnagar P, Dhote V, Mahajan S, Mishra P, Mishra D. Solid dispersion in pharmaceutical drug development: from basics to clinical applications. Curr Drug Deliv. 2014; 11(2):155-171",
            "held": false
        },
        {
            "position": 8,
            "key": "ref8",
            "doi": "10.1016/j.xphs.2015.10.008",
            "doi_url": "https://doi.org/10.1016/j.xphs.2015.10.008",
            "unstructured": "Baghel S, Cathcart H, O’Reilly NJ. Polymeric Amorphous Solid Dispersions: A Rev iew of amorphizat ion, cr yst allizat ion, stabilizat ion, solid-state characterizat ion, and aqueous solubilization of biopharmaceutical classification system class II drugs. J Pharm Sci. 2016;105(9):2527–2544",
            "held": false
        },
        {
            "position": 9,
            "key": "ref9",
            "doi": "10.1016/j.xphs.2016.08.017",
            "doi_url": "https://doi.org/10.1016/j.xphs.2016.08.017",
            "unstructured": "Huang S, Mao C, Williams III RO, Yang CY. Solubility advantage (and disadvantage) of pharmaceutical amorphous solid dispersions. J Pharm Sci. 2016; 105(12):3549-3561",
            "held": false
        },
        {
            "position": 10,
            "key": "ref10",
            "doi": "10.1002/jps.23125",
            "doi_url": "https://doi.org/10.1002/jps.23125",
            "unstructured": "Sathigari SK, Radhakrishnan VK, Davis VA, Parsons DL, Babu RJ. Amorphous-state characterization of efavirenz—polymer hot-melt extrusion systems for dissolution enhancement. J Pharm Sci. 2012; 101(9):3456–3464",
            "held": false
        }
    ]
}